NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CHLOR-TRIMETON (chlorpheniramine maleate; pseudoephedrine sulfate) by Bayer. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose and 1 more indications. First approved in 1981.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOR-TRIMETON is an oral extended-release combination antihistamine and decongestant containing chlorpheniramine maleate and pseudoephedrine sulfate. It is indicated for relief of upper respiratory allergy symptoms including runny nose, itchy/watery eyes, sneezing, and throat itching due to hay fever and other allergies. The chlorpheniramine blocks histamine receptors to reduce allergic symptoms while pseudoephedrine acts as a nasal decongestant via sympathomimetic action.
LOE Approaching
Product faces significant LOE pressure with moderate competitive intensity (30/100); legacy brand teams are typically lean and focused on retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHLOR-TRIMETON at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.